Researchers at the Icahn School of Medicine at Mount Sinai have made significant strides in reversing aging in blood-forming stem cells in mice, according to a study published in Cell Stem Cell. The investigation, led by Dr. Saghi Ghaffari, focused on the role of lysosomes—cellular structures responsible for waste recycling and nutrient storage—in the aging process of hematopoietic stem cells (HSCs).
As individuals age, HSCs, which are vital for generating blood and immune cells, experience a decline in functionality. This decline can compromise immune defense and increase susceptibility to infections and certain blood disorders, including clonal hematopoiesis, which is associated with a heightened risk of blood cancers. The study reveals that lysosomes in aged HSCs become excessively acidic and dysfunctional, leading to metabolic and epigenetic imbalances.
The researchers utilized a vacuolar ATPase inhibitor to mitigate lysosomal overactivity, effectively restoring the health and regenerative capabilities of aging stem cells. Post-treatment, these cells demonstrated enhanced ability to produce balanced blood and immune cells, improved metabolism, and reduced inflammation. Notably, the treatment increased blood-forming capacity in living animals by over eightfold.
The implications of this research are promising, potentially paving the way for new therapies aimed at addressing age-related blood disorders and improving outcomes for older patients undergoing stem cell transplants. The study suggests that targeting lysosomal dysfunction may not only help maintain healthy blood and immune systems in the elderly but could also connect normal stem cell aging with cancer development. Future research will continue to explore these connections, with funding support from various institutions, including the National Institutes of Health.